Terray Therapeutics Raises $60M in Series A Funding


Terray Therapeutics, a Pasadena, CA-based biotechnology company, raised $60M in Series A funding.

The round was led by Madrona Venture Group with participation from Two Sigma Ventures, Digitalis Ventures, KdT Ventures, Goldcrest Capital, XTX Ventures, Sahsen Ventures, Greentrail Capital and Alexandria Venture Investments.

The company intends to use the funds to advance its preclinical pipeline of therapeutics and its discovery partnerships.

Led by CEO Jacob Berlin, Terray Therapeutics is a biotechnology company that leverages AI, synthetic chemistry, automation, and nanotechnology to propel drug discovery into the information age. Terray’s proprietary integrated computational and experimental platforms generate scaled, agnostic chemical data that are purpose-built to power computational learning and reveal new interactions.

This financing follows a previously unannounced $20 million seed round co-led by Digitalis Ventures and Two Sigma Ventures.